Abstract 968P
Background
Current guidelines for hepatocellular carcinoma (HCC) screening in patients with chronic liver disease (CLD) recommend ultrasound with or without alpha-fetoprotein (AFP) every 6 months. The sensitivity of AFP and USG are low for early stage HCC. Following our previous study which identified a novel routine blood test signature for HCC, this study aims to develop a high-dimensional data classifier which accounts for the intricate interactions between these blood parameters for the detection of HCC. Its performance is then compared with AFP.
Methods
Records from 2000 to 2018 were retrieved from a population-based clinical database of >200k patients, the Hong Kong Hospital Authority Data Collaboration Laboratory. CLD (hepatitis/ cirrhosis) patients with and without HCC were identified with ICD codes, antiviral drug history, virology test and radiology reports. Decompensated cases were excluded. Blood records within one month before the diagnosis of HCC and CLD patients were retrieved. The records retrieved included all components of CBC, LFT, RFT and clotting profile. Data from 2000-2015 were split into training and testing cohorts in an 8:2 ratio while data from 2016-2018 were used as the validation set. Machine learning models were applied and their performances were compared with AFP.
Results
The cohort yielded 223,862 patients including 31,149 with HCC (45.9% hepatitis-associated) and 192,713 without. Results from the test set (n = 12528; 3279 HCC) showed promise in safely excluding non-HCC patients with a sensitivity of 90% and negative predictive value of 97%. The model’s high sensitivity maintained steady from late to early stage HCC while that of AFP halved. Our model increases HCC detection rate via USG from 19% to 50% compared to current protocol, indicating potential use in imaging prioritization and cost-saving in HCC surveillance.
Conclusions
An AI classifier for HCC detection is developed from routine blood test patient data. Its performance tested using an ultra-large cohort is consistently high without degradation across all stages with marked superiority to AFP for early stage HCC detection. Currently, multicenter prospective validation is being performed in Hong Kong.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Hong Kong University of Science and Technology.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18
957P - Interim report of Notable-HCC: A phase Ib study of neoadjuvant PD-1 with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma (HCC)
Presenter: Mingming Li
Session: Poster session 18
959P - Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial
Presenter: Lixia Ma
Session: Poster session 18
960P - Personalized circulating tumor DNA (ctDNA) monitoring for recurrence detection and treatment response assessment in hepatocellular carcinoma (HCC)
Presenter: Maen Abdelrahim
Session: Poster session 18
961P - Blood circulating Galectin-3 is a prognostic biomarker in hepatocellular carcinoma
Presenter: Shadi Chamseddine
Session: Poster session 18
962P - SBRT improves the efficacy of immuno-checkpoint inhibitors for hepatocellular carcinoma through the activation of IL-6/JAK1-STAT3/PD-L1 axis mediated by MBD3 degradation
Presenter: Weiwei Yan
Session: Poster session 18
963P - Discovery and validation of cfDNA methylation, AFP and ctDNA mutation for the early detection of hepatocellular carcinoma: A multicenter prospective study (ASCEND-Hep)
Presenter: Mingxin Pan
Session: Poster session 18
966P - Potential role of neuropilin-1 in the prognosis, development and risk of invasion in hepatocellular carcinoma patients
Presenter: Tania Payo-Serafín
Session: Poster session 18